Allogene Therapeutics Inc (OQ:ALLO)

Business Focus: Bio Therapeutic Drugs

Apr 26, 2024 08:30 am ET
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, announced that it has received a $15 million grant from the...
Apr 09, 2024 08:30 am ET
Allogene Therapeutics Announces Q2 Investor Conference Participation
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in four investor...
Mar 14, 2024 04:05 pm ET
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today provided a corporate update and reported financial...
Mar 12, 2024 08:30 am ET
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, and Arbor Biotechnologies, Inc. (“Arbor”), a biotechnology...
Mar 05, 2024 08:30 am ET
Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report fourth quarter and full...
Feb 28, 2024 08:30 am ET
Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in a panel...
Feb 16, 2024 08:30 am ET
Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Ventur
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced it will restate previously issued financial...
Jan 16, 2024 04:05 pm ET
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in three upcoming...
Jan 04, 2024 04:15 pm ET
Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lym
Allogene Therapeutics Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products, and Foresight Diagnostics (Foresight), the leader in the development of ultra-sensitive liquid...
Jan 04, 2024 04:05 pm ET
Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced its 2024 Platform Vision that redefines the...
Jan 03, 2024 04:05 pm ET
Allogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare Conference
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will host a conference call to preview its 2024 Platform...
Dec 09, 2023 12:00 pm ET
Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced the presentation of data from a comprehensive safety review of...
Dec 01, 2023 08:30 am ET
Allogene Therapeutics Announces Participation in December Investor Conference
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in one upcoming investor conference in...
Nov 03, 2023 12:00 pm ET
Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today presented preclinical data on a novel off-the-shelf AlloCAR T product...
Nov 03, 2023 12:00 pm ET
Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak™ and Dagger™ Technologies at the Society for Immunotherapy of Cancer Annual Meeting
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today presented data highlighting the Company’s next generation Cloak™ and Dagger™...
Nov 02, 2023 04:02 pm ET
Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today provided a corporate update and reported financial results for the quarter...
Nov 02, 2023 09:00 am ET
Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of Hematology
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will have two poster presentations focused on the importance...
Oct 30, 2023 08:30 am ET
Allogene Therapeutics Announces Participation in November Investor Conferences
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in two upcoming investor conferences in...
Oct 26, 2023 08:30 am ET
Allogene Therapeutics to Report Third Quarter 2023 Financial Results on November 2, 2023
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will report third quarter 2023 financial results on...
Oct 16, 2023 08:30 am ET
Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial Officer
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, has appointed Geoffrey Parker as Executive Vice President, Chief Financial Officer....
Sep 27, 2023 09:09 am ET
Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced three preclinical poster presentations at the Society for...
Sep 05, 2023 08:30 am ET
Allogene Therapeutics Announces Participation in September Investor Conference
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in an upcoming investor conference in...
Aug 14, 2023 08:30 am ET
Allogene Therapeutics Appoints Earl Douglas as General Counsel
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that Earl Douglas has been appointed as General Counsel. Mr. Douglas...
Aug 02, 2023 04:02 pm ET
Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today provided a corporate update and reported financial results for the quarter...
Jul 26, 2023 08:30 am ET
Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will report second quarter 2023 financial results on...
Jun 15, 2023 09:30 am ET
Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) Lugano
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today at the International Conference on Malignant Lymphoma (ICML) in Lugano,...
Jun 14, 2023 08:00 am ET
Allogene Therapeutics Announces Departure of Chief Financial Officer
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, announced that its Chief Financial Officer, Eric T. Schmidt, Ph.D., will step down...
Jun 09, 2023 06:25 pm ET
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced it will present data from the Phase 1 ALPHA/ALPHA2 trials of...
Jun 03, 2023 09:00 am ET
Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today presented long-term follow up data from the Phase 1 ALPHA/ALPHA2 trials of...
May 24, 2023 08:30 am ET
Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in three upcoming investor conferences. TD...
May 11, 2023 11:50 am ET
Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid Congress
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced an encore presentation of data from the Phase 1 ALPHA/ALPHA2 trials...
May 03, 2023 04:02 pm ET
Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today provided a corporate update and reported financial results for the quarter...
Apr 26, 2023 10:06 am ET
Allogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced it will present updated data from the Phase 1 ALPHA/ALPHA2 trials of...
Apr 25, 2023 08:30 am ET
Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will report first quarter 2023 financial results on...
Apr 20, 2023 04:05 pm ET
Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced the appointment of Timothy Moore to Executive Vice President, Chief...
Apr 17, 2023 10:15 am ET
Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research (AACR) Annual Meeting
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today presented interim data from its Phase 1 TRAVERSE trial of ALLO-316, the...
Apr 13, 2023 08:30 am ET
Allogene Therapeutics Announces Participation in Four Upcoming Investor Conferences
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in four upcoming investor conferences....
Mar 30, 2023 08:30 am ET
Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) Report
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today published its 2022 annual ESG report. The report provides an update on the...
Mar 14, 2023 05:30 pm ET
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual Meeting
Allogene Therapeutics, Inc. (Nasdaq: ALLO),  a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will present interim data from its Phase 1 TRAVERSE trial...
Mar 02, 2023 08:30 am ET
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in two upcoming investor conferences....
Mar 01, 2023 08:30 am ET
Allogene Therapeutics Announces Publication of Industry-Advancing Case Study on Chromosomal Rearrangement in Molecular Therapy 
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced the publication of a case review in Molecular Therapy of the single...
Feb 28, 2023 04:02 pm ET
Allogene Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today provided a corporate update and reported financial results for the quarter and...
Feb 21, 2023 08:30 am ET
Allogene Therapeutics to Report Fourth Quarter and Year-End 2022 Financial Results on February 28, 2023
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will report fourth quarter and year-end 2022 financial...
Feb 01, 2023 02:55 pm ET
Allogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T™ Platform Technology
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, presented preclinical data highlighting the Company’s next generation DaggerTM...
Jan 25, 2023 08:30 am ET
Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced the publication of a preclinical study demonstrating delta-like...
Jan 24, 2023 08:30 am ET
Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple Myeloma
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that data from its Phase 1 UNIVERSAL trial of ALLO-715, an anti-BCMA...
Jan 22, 2023 10:08 pm ET
Moore Kuehn, PLLC Encourages Investors of Allogene Therapeutics, Inc. to Contact Law Firm
Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Allogene Therapeutics, Inc. (NASDAQ: ALLO) breached their fiduciary duties to shareholders. The investigation concerns...
Jan 17, 2023 04:05 pm ET
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in two upcoming investor conferences. B....
Jan 05, 2023 12:09 pm ET
Moore Kuehn, PLLC Encourages Investors of Allogene Therapeutics, Inc. to Contact Law Firm
NEW YORK, Jan. 5, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Allogene Therapeutics, Inc. (NASDAQ: ALLO) breached their fiduciary duties to shareholders.  The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
Jan 04, 2023 08:30 am ET
Allogene Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that David Chang, M.D., Ph.D., President, Chief Executive Officer...
Jan 03, 2023 08:00 am ET
Allogene Appoints Zachary J. Roberts, M.D., Ph.D. as Executive Vice President of Research & Development
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced the appointment of Zachary J. Roberts M.D., Ph.D. to Executive Vice...
Nov 29, 2022 03:30 pm ET
Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T™ Platform
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today hosted an R&D Showcase providing an extensive overview of pipeline advances...
Nov 10, 2022 09:00 am ET
Allogene Therapeutics Unveils Novel Approach to Generate Engineered AlloCAR T™ Cells to Control Immune Rejection at the Annual Meeting of the Society for Immunotherapy of Cancer
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today presented pre-clinical data on a novel approach to immune “cloaking” designed...
Nov 09, 2022 08:30 am ET
Allogene Therapeutics To Host Research & Development Showcase and Participate in Five Upcoming Investor Conferences
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer will host a Research & Development Showcase to provide a comprehensive overview of...
Nov 03, 2022 09:04 am ET
Allogene Therapeutics Announces Poster Presentation of Its Phase 1 UNIVERSAL Trial in Multiple Myeloma at the 64th Annual Meeting of the American Society of Hematology
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will present updated data from its Phase 1 UNIVERSAL trial...
Nov 02, 2022 04:02 pm ET
Allogene Therapeutics Reports Third Quarter 2022 Financial Results and Announces Investor R&D Showcase
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today provided a corporate update and reported financial results for the quarter...
Oct 31, 2022 08:30 am ET
Allogene Overland Biopharm Completes Buildout of cGMP Manufacturing Facility in Shanghai to Support the Development of AlloCAR T™ Products in Asia
Allogene Overland Biopharm (Allogene Overland), a joint venture created by Overland Pharmaceuticals and Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™)...
Oct 26, 2022 08:30 am ET
Allogene Therapeutics to Report Third Quarter 2022 Financial Results on November 2, 2022
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will report third quarter 2022 financial results on...
Oct 11, 2022 08:30 am ET
Allogene Therapeutics Launches CAR T Together™, a First-of-its-Kind Initiative with Leading Oncologists Nationwide, Focused on Accelerating Development and Clinical Trial Recruitment for “Off-The-Shel
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today launched CAR T Together™, a first-of-its-kind effort comprised of leading...
Oct 06, 2022 04:15 pm ET
Allogene Therapeutics Initiates Industry’s First Allogeneic CAR T Phase 2 Trial
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced the initiation of the potentially pivotal Phase 2 clinical trial of...
Sep 23, 2022 08:30 am ET
Allogene Therapeutics Announces Participation in the Jefferies Cell and Genetic Medicine Summit
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that management plans to present at the Jefferies Cell and Genetic...
Aug 30, 2022 02:17 pm ET
Moore Kuehn, PLLC Encourages Investors of Allogene Therapeutics, Inc. to Contact Law Firm
Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Allogene Therapeutics, Inc. (NASDAQ: ALLO) breached their fiduciary duties to shareholders. The investigation concerns...
Aug 09, 2022 04:02 pm ET
Allogene Therapeutics Reports Second Quarter 2022 Financial Results
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today provided a corporate update and reported financial results for the quarter...
Aug 03, 2022 08:30 am ET
Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that management plans to participate in three upcoming investor...
Jul 27, 2022 08:30 am ET
Allogene Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will report second quarter 2022 financial results on...
Jul 15, 2022 09:36 am ET
Thinking about buying stock in Allogene Therapeutics, Neximmune, Vertical Aerospace, Sonim Technologies, or DigitalBridge?
NEW YORK, July 15, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ALLO, NEXI, EVTL, SONM, and DBRG.
Jul 12, 2022 08:30 am ET
Allogene Therapeutics Appoints Scientific Pioneer Stephen Mayo to its Board of Directors
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced the appointment of Stephen L. Mayo, Ph.D., a world renowned expert...
Jun 08, 2022 08:30 am ET
Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that the U.S. Food and Drug Administration (FDA) granted...
May 19, 2022 08:30 am ET
Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Improved Anti-Tumor Activity of Donor-Derived Allogeneic CAR T Cells at American Society of Gene and Cell Therapy (A
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today will present preclinical findings evaluating the characteristics and function...
May 09, 2022 08:30 am ET
Allogene Therapeutics Named 2022 Bay Area “Best Place to Work” by San Francisco Business Times and Silicon Valley Business Journal
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that the San Francisco Business Times and the Silicon Valley...
May 04, 2022 04:02 pm ET
Allogene Therapeutics Reports First Quarter 2022 Financial Results
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today provided a corporate update and reported financial results for the quarter...
Apr 28, 2022 08:30 am ET
Allogene Therapeutics Appoints Susan Lundeen as Chief People Officer
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced the appointment of Susan Lundeen as Chief People Officer effective...
Apr 27, 2022 10:01 am ET
Thinking about buying stock in Mattel, Zentalis Pharmaceuticals, Acutus Medical, Allogene Therapeutics, or NeoGenomics?
NEW YORK, April 27, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MAT, ZNTL, AFIB, ALLO, and NEO.
Apr 27, 2022 08:30 am ET
Allogene Therapeutics to Report First Quarter 2022 Financial Results on May 4, 2022
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will report first quarter 2022 financial results on...
Apr 27, 2022 08:00 am ET
Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First TurboCAR™ T Cell Product Candidate, for the Treatment of Multiple Myeloma
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted...
Apr 14, 2022 08:00 am ET
Allogene Therapeutics Unveils Cell Forge 1, a Uniquely Designed Manufacturing Facility to Deliver AlloCAR T™ Products
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced the virtual unveiling of its manufacturing facility, Cell Forge 1...
Apr 13, 2022 09:00 am ET
Allogene Therapeutics Publishes Preclinical Data on ALLO-316, an AlloCAR T™ Candidate Targeting CD70 for the Treatment of Renal Cell Carcinoma, at AACR’s Annual Meeting and in Cancer Research Journal
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that new preclinical findings of ALLO-316, an AlloCAR T therapy...
Apr 12, 2022 08:30 am ET
Allogene Therapeutics Announces Participation in Seven Upcoming Investor Conferences
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that management plans to participate in seven upcoming investor...
Mar 23, 2022 08:30 am ET
Allogene Therapeutics Announces Preclinical Publication Highlighting Superiority of Healthy Donor-Derived Allogeneic CAR T Cells Over Patient-Derived Cells in Multiple Myeloma
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced the publication of preclinical study results demonstrating the...
Mar 10, 2022 08:30 am ET
Allogene Therapeutics Receives FDA Fast Track Designation for its First Solid Tumor Candidate, ALLO-316 in the Treatment of Renal Cell Carcinoma
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast...
Mar 01, 2022 08:30 am ET
Allogene Therapeutics Publishes Inaugural Environmental, Social and Governance (ESG) Report
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today published its first ESG report. The report details the Company’s commitment to...
Feb 23, 2022 04:02 pm ET
Allogene Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today provided a corporate update and reported financial results for the quarter and...
Feb 16, 2022 08:30 am ET
Allogene Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results on February 23, 2022
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will report fourth quarter and year-end 2021 financial...
Jan 26, 2022 08:30 am ET
Allogene Therapeutics Announces Participation in Four Upcoming Virtual Investor Conferences
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in four upcoming virtual...
Jan 11, 2022 08:00 am ET
Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement with Antion Biosciences for Multiplex miCAR™ Technology
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and Antion Biosciences, a Swiss cell and gene engineering company, today announced...
Jan 10, 2022 04:30 pm ET
Cellectis’ Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical Hold on their Clinical Trials
Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today stated that its licensed partner, Allogene Therapeutics, Inc....
Jan 10, 2022 08:30 am ET
Allogene Therapeutics Announces Removal of FDA Clinical Hold Across All AlloCAR T™ Clinical Trials
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that the U.S. Food and Drug Administration (FDA) has removed the...
Jan 04, 2022 08:30 am ET
Allogene Therapeutics to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that David Chang, M.D., Ph.D., President, Chief Executive Officer...
Dec 15, 2021 08:30 am ET
Allogene Therapeutics Expands Headquarters to Support Company Growth and Pipeline Innovation
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it entered into a lease agreement to expand its headquarters...
Dec 13, 2021 11:00 am ET
Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single Dose ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 63rd American Society of Hema
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced positive updated results from the Phase 1 UNIVERSAL study of single...
Dec 13, 2021 10:30 am ET
Allogene Therapeutics Reports Positive Phase 1 Data from the ALPHA Trials in Non-Hodgkin’s Lymphoma at the 63rd Annual Meeting of the American Society of Hematology
ALPHA Trials Demonstrate Potential for AlloCAR T™ Therapy to be a Safe and Durable Alternative to Autologous Cell Therapy in CAR T Naïve PatientsAlloCAR T Therapy was Associated with Consistent and Manageable Safety with No DLTs or GvHD; Low Rates...
Dec 01, 2021 08:30 am ET
Allogene Therapeutics Announces Conference Call to Review ALPHA, ALPHA2 and UNIVERSAL Phase 1 Data Presented at the 2021 American Society of Hematology Annual Meeting
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management will host a conference call to review data to be...
Nov 12, 2021 08:30 am ET
Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Conferences
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in five upcoming virtual...
Nov 04, 2021 04:02 pm ET
Allogene Therapeutics Reports Third Quarter 2021 Financial Results and Business Update  
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today provided a corporate update and reported financial results for the quarter...
Nov 04, 2021 09:05 am ET
Allogene Therapeutics to Showcase Clinical Data from the ALPHA, ALPHA2 and UNIVERSAL AlloCAR T™ Trials at the 63rd Annual Meeting of the American Society of Hematology
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer today announced that it will present updated data from its blood cancer portfolio at...
Nov 04, 2021 02:24 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allogene Therapeutics, Inc. - ALLO
NEW YORK, Nov. 4, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Allogene Therapeutics, Inc. ("Allogene" or the "Company") (NASDAQ: ALLO).  Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
Nov 01, 2021 04:56 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allogene Therapeutics, Inc. - ALLO
Pomerantz LLP is investigating claims on behalf of investors of Allogene Therapeutics, Inc. (“Allogene” or the “Company”) (NASDAQ: ALLO).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext....
Oct 28, 2021 08:30 am ET
Allogene Therapeutics to Report Third Quarter Financial Results on November 4, 2021
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it will report third quarter 2021 financial results on...
Oct 15, 2021 09:00 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allogene Therapeutics, Inc. - ALLO
NEW YORK, Oct. 15, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Allogene Therapeutics, Inc. ("Allogene" or the "Company") (NASDAQ: ALLO).  Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
Oct 11, 2021 07:52 pm ET
Allogene Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm
The Portnoy Law Firm advises Allogene Therapeutics, Inc. ("Therapeutics" or the "Company") (NASDAQ: ALLO) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors....
Oct 11, 2021 03:17 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allogene Therapeutics, Inc. - ALLO
Pomerantz LLP is investigating claims on behalf of investors of Allogene Therapeutics, Inc. (“Allogene” or the “Company”) (NASDAQ: ALLO). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Oct 08, 2021 10:50 am ET
Thinking about buying stock in Farmmi, Tata Motors, Grom Social Enterprises, Allogene Therapeutics, or Paltalk?
NEW YORK, Oct. 8, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FAMI, TTM, GROM, ALLO, and PALT.
Oct 07, 2021 04:15 pm ET
Allogene Therapeutics Reports FDA Clinical Hold of AlloCAR T Trials Based on a Single Patient Case in ALPHA2 Trial
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today reported that following a report of a chromosomal abnormality in ALLO-501A...
Sep 20, 2021 08:30 am ET
Allogene Therapeutics Adds Renowned CAR T Expert, Jae Park, M.D. to its Scientific Advisory Board
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced the appointment of Jae Park, M.D., acting Chief of Cellular...
Sep 01, 2021 08:30 am ET
Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in two upcoming virtual...
Aug 12, 2021 08:30 am ET
Allogene Therapeutics Receives FDA Orphan Drug Designation (ODD) for ALLO-715 for the Treatment of Multiple Myeloma (MM)
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted...
Aug 04, 2021 04:02 pm ET
Allogene Therapeutics Reports Second Quarter 2021 Financial Results
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today provided a corporate update and reported second quarter 2021 financial...
Aug 02, 2021 08:30 am ET
Allogene Therapeutics Appoints Industry Leaders Elizabeth (Liz) Barrett and Vicki Sato, Ph.D., to its Board of Directors
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced the appointment of Elizabeth (Liz) Barrett and Vicki Sato, Ph.D. to...
Jul 27, 2021 08:30 am ET
Allogene Therapeutics to Report Second Quarter Financial Results on August 4, 2021
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it will report second quarter 2021 financial results on...
Jul 12, 2021 08:30 am ET
Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in two upcoming virtual...
Jun 30, 2021 08:30 am ET
Allogene Therapeutics Granted FDA Fast Track Designation for ALLO-605, the First TurboCAR™ T Cell Therapy, for the Treatment of Relapsed/Refractory Multiple Myeloma
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast...
Jun 21, 2021 07:00 am ET
Allogene Overland Biopharm Appoints Shuyuan Yao as Chief Executive Officer
Allogene Overland Biopharm (Allogene Overland), a joint venture created by Overland Pharmaceuticals and Allogene Therapeutics, Inc. (Nasdaq: ALLO), today announced the appointment of Shuyuan Yao, Ph.D. as Chief Executive Officer. Dr. Yao brings 15 years of scientific and management experience in advanced cell and gene therapy development, manufacturing and commercialization to lead Allogene Overland in its mission to bring innovative AlloCAR T™ therapies to patients in China and other Asian Pacific markets.
Jun 04, 2021 09:00 am ET
Allogene Therapeutics Presents Positive Phase 1 Data on ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma at the 2021 Annual Meeting of the American Society of Clinical Oncology
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer today presented data from multiple studies across lead anti-CD19 AlloCAR T therapy...
May 20, 2021 08:30 am ET
Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Conferences
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in five upcoming virtual...
May 19, 2021 04:51 pm ET
Allogene Therapeutics CD19 Forum Highlights Positive Results from Phase 1 Studies of ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma and Plan to Initiate Pivotal Study in 2021
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer will discuss progress on its AlloCAR T platform during today’s virtual CD19 Forum....
May 12, 2021 08:30 am ET
Allogene Therapeutics to Host Virtual CD19 Forum on May 19, 2021
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer will discuss progress on its AlloCAR T platform during a virtual CD19 Forum on May...
May 05, 2021 04:02 pm ET
Allogene Therapeutics Reports First Quarter 2021 Financial Results 
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today provided a corporate update and reported financial results for the quarter...
Apr 28, 2021 09:24 am ET
Allogene Therapeutics to Present Data from its Anti-CD19 AlloCAR T™ Therapy Program in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, in collaboration with its development partner Servier, an independent international...
Apr 27, 2021 08:30 am ET
Allogene Therapeutics to Report First Quarter Financial Results on May 5, 2021
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it will report first quarter 2021 financial results on...
Apr 21, 2021 08:30 am ET
Allogene Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to ALLO-715, an AlloCAR T™ Cell Therapy in Development for Relapsed/Refractory Multiple Myeloma
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) granted...
Apr 19, 2021 08:30 am ET
Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-605, the First TurboCAR™ Candidate, for the Treatment of Patients with Relapsed/Refractory Multiple Mye
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer today announced that the U.S. Food & Drug Administration (FDA) has cleared an...
Apr 12, 2021 08:30 am ET
Allogene Therapeutics and SpringWorks Therapeutics Announce Dosing of First Patient in Phase 1 Study Evaluating ALLO-715 in Combination with Nirogacestat in Patients with Relapsed or Refractory Multip
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer, and SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a...
Apr 10, 2021 08:30 am ET
Allogene Therapeutics Presents Preclinical Research Highlighting a Novel TurboCAR™ T Cell Technology Designed to Overcome Immune Suppression in Solid Tumors at the American Association for Cancer Rese
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced preclinical data at the American Association for Cancer Research...
Feb 25, 2021 04:02 pm ET
Allogene Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today provided a corporate update and reported fourth quarter and full year...
Feb 18, 2021 08:30 am ET
Allogene Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it will report fourth quarter and full year 2020 financial...
Feb 09, 2021 08:30 am ET
Allogene Therapeutics Announces Participation in Four Upcoming Virtual Investor Conferences
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in four upcoming virtual...
Jan 26, 2021 08:30 am ET
Allogene Therapeutics Announces Ton Schumacher, Ph.D., Chair of Scientific Advisory Board, Awarded the 2021 Jeantet-Collen Prize for Translational Medicine
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that Ton Schumacher, Ph.D., Principal Investigator at the...
Jan 05, 2021 08:30 am ET
Allogene Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that David Chang, M.D., Ph.D., President, Chief Executive Officer...
Dec 23, 2020 11:30 am ET
Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-715 in Combination with Nirogacestat in Relapsed/Refractory Multiple Myeloma
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer today announced that the U.S. Food & Drug Administration (FDA) has cleared an...
Dec 15, 2020 06:00 am ET
Allogene Therapeutics and Overland Pharmaceuticals Form Joint Venture in Greater China to Develop and Commercialize AlloCAR T™ Cell Therapies
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, and Overland Pharmaceuticals (“Overland”), a premier biopharmaceutical company...
Dec 07, 2020 10:00 am ET
Allogene Therapeutics Presents Preclinical Findings Supporting ALLO-605, the First Anti-BCMA TurboCAR™ T Cell Therapy, at the 62nd Meeting of the American Society of Hematology
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced preclinical findings of ALLO-605, the Company’s first TurboCAR™...
Dec 06, 2020 10:00 am ET
Allogene Therapeutics Presents Preclinical Data on ALLO-316 in Acute Myeloid Leukemia at the 62nd Meeting of the American Society of Hematology
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced preclinical findings of ALLO-316, an AlloCAR T™ therapy targeting...
Dec 05, 2020 12:30 pm ET
Allogene Therapeutics Reports Positive Initial Results from Phase 1 UNIVERSAL Study of ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 62nd American Society of Hematolo
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced positive initial results from the Phase 1 UNIVERSAL study of...
Dec 02, 2020 08:30 am ET
Allogene Therapeutics Announces Webinar to Review Initial ALLO-715 Phase 1 Data on December 5, 2020
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management will review initial results presented at the...
Nov 12, 2020 08:30 am ET
Allogene Therapeutics Announces November and December 2020 Virtual Investor Conference Participation
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in four investor conferences...
Nov 04, 2020 09:03 am ET
Allogene Therapeutics Announces Oral Presentation of Initial Results from its Phase 1 Dose Escalation Study of ALLO-715 in Relapsed/Refractory Multiple Myeloma at the 62nd Annual Meeting of the Ameri
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it will present initial data from its Phase 1 UNIVERSAL trial...
Nov 04, 2020 07:30 am ET
Allogene Therapeutics Reports Third Quarter 2020 Financial Results
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today provided a corporate update and reported financial results for the quarter...
Oct 27, 2020 08:30 am ET
Allogene Therapeutics to Report Third Quarter 2020 Financial Results on November 4, 2020
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it will report third quarter 2020 financial results on...
Oct 15, 2020 08:00 am ET
Allogene Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Advancement of Allogeneic CAR T Therapy (AlloCAR T™)
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, and The University of Texas MD Anderson Cancer Center today announced a strategic...
Oct 01, 2020 08:30 am ET
Allogene Therapeutics Announces October 2020 Virtual Investor Conference Participation
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in the Jefferies Virtual Cell...
Sep 02, 2020 08:30 am ET
Allogene Therapeutics Announces September 2020 Virtual Investor Conference Participation
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in the following virtual...
Aug 05, 2020 07:30 am ET
Allogene Therapeutics Reports Second Quarter 2020 Financial Results
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today provided a corporate update and reported financial results for the quarter...
Jul 28, 2020 08:30 am ET
Allogene Therapeutics to Report Second Quarter 2020 Financial Results on August 5, 2020
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it will report second quarter 2020 financial results on...
Jul 20, 2020 08:30 am ET
Notch Therapeutics Appoints David Main as President and Chief Executive Officer to Advance the Company's Novel Gene-Edited, iPSC-Derived Immune Cell Therapeutics
TORONTO, July 20, 2020 /PRNewswire/ -- Notch Therapeutics Inc., a biotechnology company creating universally compatible, off-the-shelf T cell therapies for cancer and immune disorders from renewable stem cell sources, is pleased to announce the appointment of David Main as President and Chief Executive Officer.
Jul 07, 2020 08:30 am ET
Allogene Therapeutics Adds Immunotherapy Luminaries, Thomas F. Gajewski, M.D., Ph.D., and Stephan Grupp, M.D., Ph.D., to its Scientific Advisory Board
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced the appointment of Thomas F. Gajewski, M.D., Ph.D., and Stephan...
Jul 01, 2020 08:30 am ET
Allogene Therapeutics Announces Ton Schumacher, Ph.D., Chair of Scientific Advisory Board, Awarded the Dutch Research Council’s Stevin Prize
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, announced that Ton Schumacher, Ph.D., Principal Investigator at the Netherlands...
Jun 22, 2020 04:30 pm ET
Allogene Therapeutics Presents Preclinical Findings Supporting an Allogeneic DLL3 CAR for Small Cell Lung Cancer and Development of an Inducible TurboCAR™ at the American Association for Cancer Resear
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that preclinical findings supporting DLL3-targeted AlloCAR T...
Jun 22, 2020 08:30 am ET
Allogene Therapeutics Announces Publication Highlighting Potential for ALLO-819 In Acute Myeloid Leukemia
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced a publication in Molecular Therapy demonstrating the potential for...
Jun 03, 2020 08:30 am ET
Allogene Therapeutics Announces June 2020 Virtual Investor Conference Participation
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in the following June 2020...
Jun 01, 2020 09:05 pm ET
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
Allogene Therapeutics, Inc. (Nasdaq: ALLO), today announced the pricing of an underwritten public offering of 11,702,128 shares of its common stock at a price to the public of $47.00 per share. The gross proceeds from this offering are expected to...
Jun 01, 2020 06:30 am ET
Allogene Therapeutics Announces Commencement of Public Offering of Common Stock
Allogene Therapeutics, Inc. (Nasdaq: ALLO), today announced the commencement of an underwritten public offering of $450.0 million of shares of its common stock. In addition, Allogene expects to grant the underwriters a 30-day option to purchase up...
May 29, 2020 08:00 am ET
Allogene Therapeutics, with Collaborator Servier, Reports Positive Results from its Phase 1 ALPHA Study of ALLO-501 in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Onco
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, in collaboration with development partner Servier, an independent international...
May 26, 2020 04:30 pm ET
Allogene Therapeutics Announces Webinar to Review Initial ALLO-501 Phase 1 Data on May 29, 2020
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management will review initial results from the ALLO-501 ALPHA...
May 13, 2020 05:00 pm ET
American Society of Clinical Oncology (ASCO) Abstract Reports Initial ALLO-501 ALPHA Phase 1 Data in Relapsed/Refractory Non-Hodgkin Lymphoma
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, in collaboration with its development partner Servier, an independent international...
May 06, 2020 07:30 am ET
Allogene Therapeutics Reports First Quarter 2020 Financial Results
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today provided a corporate update and reported first quarter 2020 financial results...
Apr 29, 2020 11:43 am ET
Allogene Therapeutics, in Collaboration with Servier, to Present Initial Results from its Phase 1 ALPHA Study of ALLO-501 AlloCAR T™ Therapy in Relapsed/Refractory Non-Hodgkin Lymphoma at the American
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, in collaboration with its development partner Servier, an independent international...
Apr 28, 2020 04:39 pm ET
Allogene Therapeutics to Present Preclinical Findings Supporting TurboCAR™ Technology at the American Society of Gene & Cell Therapy (ASGCT) Virtual 2020 Annual Meeting
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer, today announced that preclinical data on its TurboCAR™...
Apr 27, 2020 08:30 am ET
Allogene Therapeutics to Report First Quarter 2020 Financial Results on May 6, 2020
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it will report first quarter 2020 financial results on...
Apr 01, 2020 08:30 am ET
Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in two upcoming virtual...
Mar 24, 2020 07:00 am ET
MaxCyte and Allogene Therapeutics Sign Clinical and Commercial License Agreement to Enable the Advancement of Allogeneic CAR T (AlloCAR T™) Therapies
GAITHERSBURG, Md. and SOUTH SAN FRANCISCO, Calif., March 24, 2020 /PRNewswire/ -- MaxCyte, Inc., a global cell-based therapies and life sciences company, and Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced a clinical and commercial license agreement. Under the terms of the agreement, Allogene gains rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to develop and advance its AlloCAR T™ candidates through to commercialization. In retur
Feb 27, 2020 04:30 am ET
Allogene Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today provided a corporate update and reported fourth quarter and full-year 2019...
Feb 19, 2020 08:30 am ET
Allogene Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on February 27, 2020
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it will report fourth quarter and full year 2019 financial...
Feb 06, 2020 08:30 am ET
Allogene Therapeutics Announces February and March 2020 Investor Conference Schedule
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to present at two investor conferences for...
Jan 13, 2020 06:00 am ET
Allogene Therapeutics and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate ALLO-715 in Combination with Nirogacestat in Multiple Myeloma
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer and SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a...
Jan 02, 2020 08:30 am ET
Allogene Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer, today announced that David Chang, M.D., Ph.D.,...
Nov 11, 2019 08:30 am ET
Allogene Therapeutics Announces Year-End 2019 Media Event and Investor Conference Schedule
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to present at two media events through the...
Nov 06, 2019 09:02 am ET
Allogene Therapeutics Announces Pre-Clinical Data Presentations Supporting AlloCAR T™ Pipeline at 61st American Society of Hematology Annual Meeting
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer, today announced that it will present data supporting its...
Nov 05, 2019 07:30 am ET
Allogene Therapeutics Reports Third Quarter 2019 Financial Results
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today provided a corporate update and reported financial results for the quarter...
Nov 05, 2019 06:28 am ET
Allogene Therapeutics and Notch Therapeutics Announce Collaboration to Research and Develop Induced Pluripotent Stem Cell (iPSC)-Derived Allogeneic Therapies for Hematologic Cancer Indications
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, and Notch Therapeutics Inc., an immune cell therapy company creating universally...
Oct 29, 2019 08:30 am ET
Allogene Therapeutics to Report Third Quarter 2019 Financial Results on November 5, 2019
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it will report third quarter 2019 financial results on...
Sep 19, 2019 08:00 am ET
Allogene Therapeutics Enters Research Collaboration Directed at Enhancing Future Cancer Immunotherapies
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it has entered into a research collaboration agreement with...
Sep 03, 2019 08:30 am ET
Allogene Therapeutics Announces September 2019 Investor Conference Schedule
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to present at the Morgan Stanley 17th Annual...
Aug 07, 2019 07:30 am ET
Allogene Therapeutics Reports Second Quarter 2019 Financial Results
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today provided a corporate update and reported financial results for the quarter...
Aug 05, 2019 06:00 am ET
Allogene Therapeutics Appoints Rafael G. Amado, M.D. as Executive Vice President of Research and Development and Chief Medical Officer
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced the appointment of Rafael G. Amado, M.D., as Executive Vice...
Jul 29, 2019 08:30 am ET
Allogene Therapeutics to Report Second Quarter 2019 Financial Results on August 7, 2019
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it will report second quarter 2019 financial results on...
Jun 04, 2019 07:45 am ET
Allogene Therapeutics Announces FDA Clearance of the IND for ALLO-715, a BCMA Allogeneic CAR T (AlloCAR T™) Therapy
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that the U.S. Food & Drug Administration (FDA) has cleared...
May 29, 2019 08:30 am ET
Allogene Therapeutics Announces June 2019 Investor Conference Schedule
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to present at three investor conferences in...
May 07, 2019 07:30 am ET
Allogene Therapeutics Reports First Quarter 2019 Financial Results
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today provided a corporate update and reported financial results for the quarter...
May 01, 2019 08:30 am ET
Allogene Therapeutics Announces Expansion of Scientific Advisory Board
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced the appointment of Robert Abraham, Ph.D., Malcolm K. Brenner, M.D.,...
Apr 30, 2019 08:30 am ET
Allogene Therapeutics to Report First Quarter 2019 Financial Results on May 7, 2019
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it will report first quarter 2019 financial results on...
Apr 15, 2019 08:00 am ET
Allogene Therapeutics Announces Publication of Preclinical Study Results in Molecular Therapy Highlighting Potential for ALLO-715 (an Anti-BCMA AlloCAR T™ Therapy) in Multiple Myeloma
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced the publication of preclinical study results of ALLO-715, an...
Apr 03, 2019 04:30 pm ET
Allogene Therapeutics Announces April 2019 Investor Conference Schedule 
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to present at the Jefferies Immuno-Oncology...
Apr 01, 2019 01:00 pm ET
Allogene Therapeutics Presents Preclinical Data Demonstrating the Potential of AlloCAR T™ Therapy in Renal Cell Carcinoma (RCC) at the 2019 AACR Annual Meeting
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced results from a preclinical study of its AlloCAR T program targeting...
Mar 08, 2019 08:00 am ET
Allogene Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today provided a corporate update and reported fourth quarter and full-year 2018...
Feb 27, 2019 08:00 am ET
Allogene Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results on March 8, 2019
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it will report fourth quarter and full year 2018 financial...
Feb 20, 2019 08:00 am ET
Allogene Therapeutics Enters Lease to Build Manufacturing Facility to Develop and Commercialize Allogeneic CAR T (AlloCAR T™) Therapies
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it has entered into a lease agreement to develop a 118,000...
Feb 05, 2019 08:00 am ET
Allogene Therapeutics Announces February and March 2019 Investor Conference Schedule
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to present at four investor conferences in...
Jan 28, 2019 08:30 am ET
Allogene Therapeutics, in Collaboration with Servier, Announces FDA Clearance of the IND for ALLO-501, an anti-CD19 Allogeneic CAR T (AlloCAR T™) Therapy
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, in collaboration with its development partner Servier, an independent international...
Dec 19, 2018 08:00 am ET
Allogene Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that David Chang, M.D., Ph.D., President, Chief Executive Officer...
Dec 03, 2018 07:45 pm ET
Allogene Therapeutics and Servier Present Pooled Data from Phase 1 Trials of Allogeneic UCART19 in Relapsed/Refractory Acute Lymphoblastic Leukemia  
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, and Servier, an independent international pharmaceutical company, today announced...
Dec 03, 2018 10:30 am ET
Allogene Therapeutics Presents Data from Preclinical Study of ALLO-715 (anti-BCMA) Demonstrating Allogeneic CAR T Potential in Multiple Myeloma at the 2018 ASH Annual Meeting
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced results of a preclinical study of ALLO-715, an AlloCAR T therapy...
Nov 05, 2018 08:00 am ET
Allogene Therapeutics Announces November 2018 Investor Conference Schedule
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to present at two investor conferences in...
Nov 01, 2018 09:26 am ET
Allogene Therapeutics Announces Data Presentations Supporting Its Allogeneic CAR T Pipeline Program at 60th American Society of Hematology (ASH) Annual Meeting
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it will present data supporting its allogeneic pipeline program during the 60th American Society of Hematology (ASH) Annual Meeting & Exposition, taking place December 1-4 at the San Diego Convention Center.
Oct 15, 2018 04:30 pm ET
Allogene Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced the closing of its previously announced initial public offering of 20,700,000 shares of its common stock, which includes 2,700,000 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of $18.00 per share. Including the option exercise, the gross proceeds to Allogene Therapeutics
Oct 12, 2018 01:15 pm ET
Nasdaq Welcomes Allogene Therapeutics, Inc. (Nasdaq: ALLO) To The Nasdaq Stock Market
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, rang the opening bell at the Nasdaq MarketSite in Times Square today in celebration...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.